Efficacy of a novel injectable cephalosporin, Cefclidin, on the experimental complicated urinary tract infections with urinary stones caused by Pseudomonas aeruginosa and Proteus mirabilis

Abstract

Imipenem (IPM)感受性および耐性のPseudomonas aeruginosaとProteus mirabilisによる感染性膀胱結石を伴う新規ラット複数菌尿路感染モデルを用いて, 尿, 膀胱結石および腎からの除菌および感染性膀胱結石の形成抑制に対するセフクロジン(CFCL)およびチェナム(IPM)の効果を評価した。CFCLは, 5日間(20mg/kg, b.i.d)の短期投与で尿および結石中からProteus mirabilisを完全に除菌した。CFCLは, 11日間の長期投与でIPMと比較した時, 尿, 膀胱結石および腎からIPM感受性および耐性のPseudomonas aeruginosaを完全に除菌した。また, CFCLは, 長期投与で, 感染結石の成長を有意に抑制した

We evaluated the effects of a novel cephalosporin, cefclidin (CFCL) and imipenem (IPM), on the eradication of bacteria from the urine, bladder stones and the kidneys, and also on the prevention of the infection stone formations, in our polymicrobial urinary tract infection model of rats associated with bladder stones using IMP-sensitive or IPM-resistant Pseudomonas aeruginosa and Proteus mirabilis as a causative pathogen. CFCL completely eradicated P. mirabilis from the urine and the stone in the short-term regimen (5 days). CFCL completely eradicated both IPM-sensitive P. aeruginosa and P. mirabilis from the urine, the stones and the kidneys as compared to IPM in the long-term regimen (11 days), reflecting the superior antibacterial activity of CFCL. CFCL also significantly prevented the development of infection stones as compared to IPM in the long-term regimen. There was no significant difference in the blood urea nitrogen (BUN) values between the CFCL or IPM-treated and the non-treated groups. The cumulative recovery rate of unchanged CFCL reached 47.3% of the total dosage (20 mg/kg) within 8 hours.